QbDVision secures $13MM in strategic investment to accelerate Digital CMC transformation and product lifecycle management for enterprise pharma and biotech
Too Long; Didn’t Read? Here’s the gist:
New capital infusion for QbDVision secured through top-tier enterprise customer acquisition, successful global deployments, and the increased demand for its category-defining Digital CMC platform. Today, their customers include three of the top six global pharma and biotech companies.
Industry growth coupled with geopolitical uncertainty is driving unprecedented demand for CMC (chemistry, manufacturing, and controls) transformation. Realizing that data-only strategies are insufficient, the industry is embracing digital, knowledge-based business processes and is gaining momentum to improve operational efficiency.
QbDVision is the force behind this fundamental shift as the creator and market leader of the Digital CMC software category that’s enabling tomorrow’s AI-powered pharmaceutical industry.
To accelerate growth and solidify its market leadership, QbDVision announces two strategic appointments, Mike Stapleton as Chief Business Officer and Chas Peacock as VP of Engineering
QbDVision is poised to navigate today’s market uncertainty, regulatory dynamics, and supply chain disruption, empowering a smarter, more agile future for biopharma.
After a year of breakthrough successes, QbDVision has secured $13M in additional investment fueled by rapid enterprise customer growth that now includes three of the top six pharma and biotech companies, successful global deployments, and the increased demand for its category-defining Digital CMC platform, which addresses the increasing need for digitalization of development and manufacturing work streams across the entire product lifecycle for pharma and biotech.
Led by prior investors Northpond Ventures and S3 Ventures, along with Create Health Ventures and company insiders, this new capital infusion accelerates the realization of our shared vision and the opportunity at hand: solidifying QbDVision as the digital knowledge backbone for Chemistry, Manufacturing, and Controls (CMC) workflows that will enable tomorrow’s AI-powered pharmaceutical industry.
Industry Momentum: CMC transformation takes center stage
The industry is now at a tipping point, and CMC has hit center stage for digital transformation. Drug sponsors are re-engineering CMC workflows and business processes to reduce the lifecycle of development. We’re seeing regulatory bodies working on structured CMC data and knowledge initiatives to accelerate the review of submissions. International organizations and industry groups are prioritizing data standards (e.g., taxonomy or ontologies). With the realization that data-only strategies are not sufficient to handle these seismic challenges, the shift to digital, knowledge-based business processes to improve operational efficiency is happening across the industry.
“CMC knowledge is a key asset for any company developing new therapies”, Yash Sabharwal, President, CEO, and Co-Founder at QbDVision, notes. “As organizations look for ways to accelerate the development of complex modalities and navigate both regulatory and market uncertainty, they need contextualized understanding of their CMC operations, and QbDVision is increasingly the solution of choice to meet this need.”
Further, as the world economy moves away from globalization and more manufacturing activities are onshored, the ability to manage and transfer CMC knowledge quickly will become even more critical. This is yet another reason why leading enterprise companies continue to select QbDVision to accelerate CMC digital transformation within their organizations.
CMC Knowledge: The catalyst to unlock operational excellence and AI’s true potential
QbDVision has enabled the first fundamental shift required for digital transformation. A movement away from siloed, document-centric legacy approaches and towards an integrated platform where CMC data is converted into information and knowledge. QbDVision is the force that can finally bring down the old barriers between teams, sites, organizations, and regulatory agencies.
“We are following the same path for CMC operations that was taken by the discovery world to build the AlphaFold models for prediction and optimization of proteins,” Yash notes. “AlphaFold was not trained directly on lots of data from the internet, it was trained on using highly structured and curated knowledge models of protein structure and function. This is fundamental to QbDVision’s vision and why we are the most comprehensive solution for converting CMC data models into structured, curated, and domain-specific knowledge models.”
Just as AlphaFold required specific, reliable scientific information to build powerful predictive models to unlock the power of AI in drug development, the predictive CMC models of the future will require the trustworthy, highly-contextualized CMC knowledge that QbDVision delivers.
“It’s the knowledge backbone that unlocks tomorrow’s AI-powered industry,” affirms Paxton Major, Managing Director at Northpond Ventures. “That’s what makes it so exciting to further our partnership with QbDVision. Their innovative platform combined with their pioneering vision can fundamentally alter the way our industry executes. Laying the foundation for intelligent, AI-powered pharma operations built on CMC knowledge. A shared source of truth that spans the entire product life cycle and can unlock an organization’s true potential.”
“That’s what makes it so exciting to further our partnership with QbDVision. Their innovative platform combined with their pioneering vision can fundamentally alter the way our industry executes. Laying the foundation for intelligent, AI-powered pharma operations built on CMC knowledge. A shared source of truth that spans the entire product life cycle and can unlock an organization’s true potential.
Scaling Up: Key management hires to accelerate growth and solidify market leadership
To meet increasing market demand and capitalize on significant growth opportunities, QbDVision has bolstered its leadership team with the appointment of two key executives.
A digital pioneer and leading voice in life science innovation, Mike Stapleton is stepping in from QbDVision’s board into a key leadership position as Chief Business Officer. Mike has already made an impact spear-heading the launch of Project Artemis, a pre-competitive collaboration that’s geared towards building a connected data ecosystem to enable industry-wide CMC transformation. Now, he’ll play a pivotal role in expanding our strategic agenda and forging new growth opportunities.
“From my experience on the board, I’ve seen QbDVision’s tremendous potential. Moving into this role full-time allows me to directly contribute to and accelerate our strategic vision, ensuring we capitalize fully on our market momentum,” Mike notes. “This strategic investment allows us to aggressively scale key enterprise accounts and solidify our market leadership.”
At the same time, to begin rapid scaling of our product and engineering teams, Chas Peacock has joined QbDVision, as VP of Engineering. “As we scale, my primary objective is to ensure the best possible product experience for QbDVision’s customers,” Chas emphasizes. “To ensure this, our approach can’t just be about hiring more people, it needs to continue to be culture-led and allow innovation to flourish. We’re focusing on attracting talented individuals who are motivated by our mission, and ensuring they have the resources they need to thrive.”
After being ranked as one of the fastest-growing companies on the 2025 Inc. Regionals: Southwest list by Inc. Magazine, QbDVision is entering its next phase by continuing to lead the Digital CMC movement and help the world’s most innovative drug developers bring therapies to patients with greater speed and certainty.
“From my experience on the board, I've seen QbDVision’s tremendous potential. Moving into this role full-time allows me to directly contribute to and accelerate our strategic vision, ensuring we capitalize fully on our market momentum,”
What’s next: Empowering a smarter, more agile future for biopharma
This funding isn’t just a win for us—it’s a clear signal that Digital CMC is becoming an essential part of the digital ecosystem for biopharma. It accelerates our journey to build the digital foundation for the future of medicine. Transforming CMC data from a historical bottleneck into a strategic asset. Paving the way for faster innovation, enhanced industry collaboration and the timely delivery of critical therapies to patients.
As the life sciences landscape continues to face unprecedented market volatility, evolving regulatory expectations, and growing supply chain disruption, QbDVision can offer organizations the ability to not only adapt quickly to these market conditions —but thrive in them.
Media inquiries
About QbDVision
QbDVision is a structured, cloud-based platform designed to empower teams with unified knowledge of their product and manufacturing process, while automating key development workflows throughout the entire product lifecycle journey. Unlike other traditional product lifecycle management (PLM) solutions, QbDVision’s Digital CMC platform is purpose-built for biopharma organizations to accelerate the development of life-changing therapies as they transition from R&D to Commercial Manufacturing. Teams can now leverage robust CMC knowledge that provides real-time guidance for enhanced data-driven decision making and streamlines complex operational workflows that reduces cycle times, while ensuring quality and compliance.
Learn more >
GET IN TOUCH
Ready to join our journey?
It’s about to enter a new powerhouse phase. Want to be part of it? Visit our careers page to explore opportunities to join our growing team.
